The effects of the farnesyl transferase inhibitor FTI L-778,123 on normal, myelodysplastic, and myeloid leukemia bone marrow progenitor proliferation in vitro

X. K. Huang, P. Meyer, B. Li, A. Raza, H. D. Preisler

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations

Abstract

The effects of the farnesyl transferase inhibitor FTI-778,123 on the proliferation of normal, MDS, AML, and CML hemopoietic progenitor cells was studied. MDS myeloid and erythroid progenitors are significantly more sensitive to FTI than normal progenitors while AML myeloid progenitors may be somewhat more sensitive than normal progenitors. In contrast, no difference between CML and normal progenitors are detectable. These data strongly suggest that a trial of this agent in patients with MDS and perhaps in patients with AML is indicated.

Original languageEnglish (US)
Pages (from-to)157-164
Number of pages8
JournalLeukemia and Lymphoma
Volume44
Issue number1
DOIs
StatePublished - Jan 1 2003
Externally publishedYes

Keywords

  • Bone marrow progenitor cells
  • FTI L-778,123
  • Farnesyl transferase inhibitor
  • Myelodysplasia
  • Myeloid leukemia
  • Normal progenitors

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The effects of the farnesyl transferase inhibitor FTI L-778,123 on normal, myelodysplastic, and myeloid leukemia bone marrow progenitor proliferation in vitro'. Together they form a unique fingerprint.

Cite this